bioMérieux 미래 성장

Future 기준 확인 3/6

bioMérieux (는) 각각 연간 14.1% 및 7.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 14% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 12.4% 로 예상됩니다.

주요 정보

13.5%

수익 성장률

13.5%

EPS 성장률

Medical Equipment 수익 성장	19.0%
매출 성장률	7.4%
향후 자기자본 수익률	12.8%
애널리스트 커버리지	Good
마지막 업데이트	17 Oct 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

WBAG:BIM - 애널리스트의 미래 추정치 및 과거 재무 데이터 (EUR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	4,543	604	422	866	12
12/31/2025	4,217	533	377	804	13
12/31/2024	3,934	470	355	726	13
6/30/2024	3,807	411	156	495	N/A
3/31/2024	3,741	384	132	470	N/A
12/31/2023	3,675	358	107	445	N/A
9/30/2023	3,688	372	140	459	N/A
6/30/2023	3,701	386	172	472	N/A
3/31/2023	3,645	419	180	474	N/A
12/31/2022	3,589	452	188	475	N/A
9/30/2022	3,525	502	297	583	N/A
6/30/2022	3,460	552	406	690	N/A
3/31/2022	3,418	577	470	757	N/A
12/31/2021	3,376	601	535	825	N/A
9/30/2021	3,296	555	424	716	N/A
6/30/2021	3,216	509	314	608	N/A
3/31/2021	3,167	457	310	595	N/A
12/31/2020	3,118	404	305	583	N/A
9/30/2020	2,997	355	261	538	N/A
6/30/2020	2,876	305	217	493	N/A
3/31/2020	2,775	289	176	451	N/A
12/31/2019	2,675	273	135	408	N/A
9/30/2019	2,601	268	160	419	N/A
6/30/2019	2,527	263	185	431	N/A
3/31/2019	2,474	260	179	415	N/A
12/31/2018	2,421	257	173	400	N/A
9/30/2018	2,372	264	162	370	N/A
6/30/2018	2,323	271	150	340	N/A
3/31/2018	2,306	255	N/A	341	N/A
12/31/2017	2,288	238	N/A	341	N/A
9/30/2017	2,262	216	N/A	340	N/A
6/30/2017	2,237	195	N/A	339	N/A
3/31/2017	2,170	187	N/A	337	N/A
12/31/2016	2,103	179	N/A	336	N/A
9/30/2016	2,068	158	N/A	339	N/A
6/30/2016	2,032	137	N/A	342	N/A
3/31/2016	1,998	124	N/A	326	N/A
12/31/2015	1,965	111	N/A	310	N/A
9/30/2015	1,908	127	N/A	N/A	N/A
6/30/2015	1,851	144	N/A	301	N/A
3/31/2015	1,775	140	N/A	300	N/A
12/31/2014	1,698	135	N/A	298	N/A
9/30/2014	1,656	135	N/A	N/A	N/A
6/30/2014	1,614	135	N/A	246	N/A
3/31/2014	1,601	150	N/A	243	N/A
12/31/2013	1,588	164	N/A	241	N/A

애널리스트 미래 성장 예측

수입 대 저축률: BIM 의 연간 예상 수익 증가율( 14.1% )이 saving rate( 1.1% 보다 높습니다. ).

수익 vs 시장: BIM 의 연간 수익( 14.1% ) Austrian 시장( 4.3% 보다 빠르게 성장할 것으로 예상됩니다. 4.3% 연간).

고성장 수익: BIM 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: BIM 의 수익(연간 7.1% ) Austrian 시장( -2.6% 보다 빠르게 성장할 것으로 예상됩니다. -2.6% 연간).

고성장 수익: BIM 의 수익(연간 7.1% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: BIM 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 12.4 %).

bioMérieux 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Recent updates

First half 2024 earnings released: EPS: €1.83 (vs €1.37 in 1H 2023)

bioMérieux Announces USDA-FSIS Field Service Laboratories Selects GENE-UP Pathogenic E. coli Assay as Primary Method for Shiga Toxin-Producing E. coli Detection

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Upcoming dividend of €0.85 per share

bioMérieux S.A. to Report First Half, 2024 Results on Sep 05, 2024

New minor risk - Earnings quality

Dividend of €0.85 announced

Full year 2023 earnings released: EPS: €3.03 (vs €3.84 in FY 2022)

bioMérieux S.A., Annual General Meeting, May 23, 2024

First half 2023 earnings released: EPS: €1.37 (vs €1.93 in 1H 2022)

Upcoming dividend of €0.85 per share at 0.9% yield

Full year 2022 earnings released: EPS: €3.84 (vs €5.08 in FY 2021)

bioMérieux Introduces GENE-UP ENVIROPRO

bioMérieux S.A. to Report Fiscal Year 2022 Results on Mar 08, 2023

bioMérieux and Jackson Family Wines Introduces Innovation for Wine Quality - BOTTLESAFE™

Investor sentiment deteriorated over the past week

First half 2022 earnings released: EPS: €1.93 (vs €2.34 in 1H 2021)

Now 21% undervalued

Now 22% undervalued

Upcoming dividend of €0.85 per share

bioMérieux Receives Health Canada Approval for BIOFIRE® Blood Culture Identification 2 (BCID2) Panel for Rapid Molecular Bloodstream Infection Identification

bioMérieux Receives Health Canada Approval for BIOFIRE® Blood Culture Identification 2 (BCID2) Panel for Rapid Molecular Bloodstream Infection Identification

Insufficient new directors

bioMérieux S.A., Annual General Meeting, May 23, 2022

bioMérieux S.A. (ENXTPA:BIM) entered into an agreement to acquire remaining unknown shares in Specific Diagnostics, LLC for €360 million.

bioMérieux S.A. (ENXTPA:BIM) entered into an agreement to acquire Specific Diagnostics, LLC.

Now 25% undervalued after recent price drop

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

bioMérieux Achieves First-Ever AOAC INTERNATIONAL Approval for PCR Multiplex Detection of STEC and Salmonella in Cannabis Flower for the GENE-UP® PRO STEC/ Salmonella Assay

First half 2021 earnings released: EPS €2.34 (vs €1.46 in 1H 2020)

Full year 2020 earnings released: EPS €3.42 (vs €2.31 in FY 2019)

Revenue misses expectations

Full year 2020 earnings released: EPS €3.42 (vs €2.31 in FY 2019)

New 90-day low: €111

bioMérieux S.A., Annual General Meeting, May 20, 2021

bioMérieux S.A. Announces the Expansion of the Ce Marking of Its Molecular Biology Argene® Sars-Cov-2 Diagnostic Test to Include Saliva Specimens

bioMérieux Launches Predictive Diagnostics, Pairing Microbiology Solutions with Data Science, Sequencing and Predictive Modeling

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견